LTZ 301
Alternative Names: LTZ-301Latest Information Update: 01 Aug 2024
At a glance
- Originator LTZ Therapeutics
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators; Macrophage stimulants; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Chronic lymphocytic leukaemia; Follicular lymphoma; Non-Hodgkin's lymphoma